semaglutide pill form over the counter U.S. Food and Drug Administration approved Novo Nordisk's oral (Wegovy) as the first GLP-1 for obesity and cardiovascular risk reduction, with the company targeting an early 2026 launch. Novo Oral Semaglutide for Weight Loss

362 Considering the expression of the GLP-1R in thyroid C cells and the ability of GLP-1 to stimulate calcitonin secretion through a cAMP-mediated mechanism in vitro, it is plausible that calcitonin plays a role in the alterations in bone metabolism observed in GLP-1R-treated animals

"This is the start of a new era of effective treatments for obesity," he said

Both products carry a boxed warning for medullary thyroid carcinoma (MTC) and are contraindicated with MEN2 or a personal/family history of MTC

12 , R33 (2010)

Monitor Physical Activity While regular exercise is important for overall health and weight maintenance, you may need to temporarily modify intensity or duration if experiencing significant fatigue